US Tocilizumab Race Heats Up As Biogen Matches Kabi’s Filing
Biogen Filed With EMA In September; US Sponsors Line Up 2023 Launches
In a small pool of developers, Biogen has matched Fresenius Kabi by filing its proposed tocilizumab biosimilar with the US Food and Drug Administration.
